Pharmacotherapy for Prevention and Management of Thrombosis in COVID-19

Semin Thromb Hemost. 2020 Oct;46(7):789-795. doi: 10.1055/s-0040-1714273. Epub 2020 Aug 20.
No abstract available

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents / pharmacokinetics
  • Anti-Inflammatory Agents / therapeutic use
  • Anticoagulants / adverse effects
  • Anticoagulants / pharmacokinetics
  • Anticoagulants / therapeutic use*
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • Coronavirus Infections / blood*
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy
  • Drug Administration Routes
  • Drug Interactions
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / pharmacokinetics
  • Fibrinolytic Agents / therapeutic use*
  • Hemostasis / drug effects
  • Humans
  • Pandemics*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Pneumonia, Viral / blood*
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy
  • SARS-CoV-2
  • Thrombophilia / drug therapy*
  • Thrombophilia / etiology
  • Thrombosis / drug therapy
  • Thrombosis / etiology
  • Thrombosis / prevention & control*
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / etiology
  • Venous Thromboembolism / prevention & control

Substances

  • Anti-Inflammatory Agents
  • Anticoagulants
  • Antiviral Agents
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors